![](https://www.diabetesnews.com/wp-content/uploads/2013/06/pills_redwhite_wideweb__470x3160-150x150.jpg)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA®
Read more
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA®
Read more